Concordia Healthcare to purchase AMCo
UK-based global pharmaceutical company, AMCo, is to be bought by the Canadian healthcare business Concordia
UK-based global pharmaceutical company, AMCo, is to be bought by Concordia, a diverse Canadian healthcare company focused on legacy pharmaceutical products and orphan drugs. The acquisition creates a leading international pharmaceutical company with products available in more than 100 countries and operations in many of the major pharmaceutical markets in the world.
AMCo welcomes this acquisition by Concordia. John Beighton, Chief Executive Officer of AMCo, said: ‘We look forward to being part of the Concordia business. We believe everyone will benefit and that it will increase patients’ access to medicines. We have a shared vision for growth that should greatly benefit employees and stakeholders of the combined business.’
The combined company will have an extensive geographic reach, a diversified and attractive product portfolio and the ability to further invest in optimising medicines. ‘We are not only acquiring products and commercial infrastructure, but a seasoned management team who has done a fantastic job of building a solid and successful international operation,' said Mark Thompson, Concordia’s Chairman and Chief Executive Officer. 'The combination of our highly complementary yet geographically diverse businesses is truly transformational.’
AMCo has advised its customers, suppliers, staff and business partners that it is ‘business as usual.’ There will be no change in the teams or the way the company works with other businesses.
